Tag: Glucagon-Like Peptide-1 (GLP-1) Receptor

By Posted on Posted in Adverse Drug Reaction [ADR], Genetic Background, Genetic Predisposition, Genetic Susceptibility, Personalized Medicine, Thasso Post, Theragenomic Medicine Tagged with , , , , , , , , , , , , , , , , , , , , ,

December 20, 2018 – This is very troubling news for all patients worldwide with diabetes and who are under therapy with drugs out of the DPP-4 class of inhibitors:  A very recent population-based epidemiological study indicates that patients under DPP-4 inhibitors …

Cholangiocarcinoma: Diabetes Drugs In DPP-4 Inhibitor Class Associated With Doubled Risk Read more »

By Posted on Posted in New Drug Approval, Thasso Post Tagged with , , , , , , , , , , , ,

December 23, 2014 – The U.S. Food and Drug Administration (FDA) just approved Saxenda (liraglutide [rDNA origin] injection) as a treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity. The drug is approved for use …

The weight-management drug Liraglutide (Saxenda) has just been approved by the FDA Read more »